Mission Statement
Providing Tomorrow's Innovative Solution's Today®
Our mission is to discover, develop and successfully market innovative products in the animal and human food industry, that enhances the quality of life. We also want to build a reputation for being creative and employing cutting edge technologies for developing bioactive products.
Our Aspirations
Our vision for the company is to become "a global leader in the discovery, development, and marketing of environmentally friendly, natural or nature identical bioactive compounds". Our wish is to continue to strengthen our position in the markets we currently serve and employ our biotechnology and biologics approach to capitalize on new opportunities in the Dietary Supplement, Pharmaceutical, Animal Health and Agriculture markets. Key elements of our strategy include:
- Leverage our technology platforms to develop products that address the growing need for environmentally friendly and natural solutions in these target markets.
Arkion® has technologies and products that provide new and unique, lower-cost and lower-capital investment processes to make proprietary products. These products do not have the toxicity, side effects and negative public perception that are characteristics of many existing products in the same market.
Antibiotics and synthetic drugs are coming under increasing scientific and public scrutiny in both animal and human applications. Because of public concerns about pathogens developing resistance to antibiotics and side effects encountered with the use of many synthetic drugs, pressure to reduce the use of these compounds has been significant. Arkion® has viable natural alternative solutions to some of these situations.
The need for vitamins and many other fine chemicals is growing at high rates and require new high capacity investments using complex synthetic chemical processes. Arkion® has biotechnology alternatives that will result in significantly lower capital and operating costs.
Arkion® has developed bioactive, humane solutions to insect and bird control problems. As the bird population increases, birds are becoming a serious health and economic problem. There are currently no other effective and humane alternative control methods available.
- Continue to develop unique hyperimmune products for the Dietary Supplement, Animal Health and Biosecurity Areas.
In the dietary supplement area, we will continue to develop products for Legacy for Life and sell through a subsidiary (Arkion® International LLC) to Africa when that major market develops. Arkion® will continue to develop a strong proprietary position including composition of matter patents on unique immune factors.
- Expedite market introduction of pipeline products in the Dietary Supplement, Animal Health and Agriculture segments.
We intend to increase our investment in research and development to enhance our existing technology platforms, staying focused in the development of our existing pipeline. We believe this increase, combined with our proven ability to commercialize products, will accelerate our product development efforts and allow us to successfully capture the growth opportunities in our target markets.
- Pursue long-term strategic alliances with industry leaders in the Pharmaceutical, Specialty Chemical, Animal Health and Crop Protection fields to expedite development and introduction of pipeline products in these industries.
We intend to establish long-term strategic alliances with industry leaders, who will provide access to sales and marketing expertise and distribution channels across our target markets. We expect to structure these partnerships as JV's, marketing, or supply relationships, with a combination of up-front payments, research and development funding, milestone payments and royalties. We intend to continue to retain a proprietary interest in the products and technology that we develop with these partners, as well as the related manufacturing rights, allowing us to leverage our discoveries into other market segments.
- Make selected enabling technology and business acquisitions to increase the critical mass in our core businesses and technologies.
We have in the past acquired technologies and businesses and integrated those successfully into our operations. We will continue to identify, evaluate and acquire or license enabling technologies to enhance our technology platforms. We will continue to explore acquisitions of strategic businesses and technologies to expand our market presence and to enhance our technology platforms and businesses.